Free tool
Rare disease stocks
We cover 18 companies grouped under the Rare disease theme. The median market value in the group is $1.51B. Across the group, the median move over the past trading day is +0.04%. Price change over the past year runs from +25.7% to +410.0% across the middle 80 percent of the group, with a median of +127.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
18 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $549.02 | +0.13% | +22.11% | +40.77% | Nov 2, 2026 |
| ARGX | argenx SE | $1,047.10 | +20.05% | +24.66% | +47.90% | Oct 22, 2026 |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.19 | +0.05% | +11.54% | +15.03% | Oct 26, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $84.84 | +1.17% | +81.55% | +179.08% | Nov 5, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $37.08 | +89.67% | +224.69% | +292.38% | Nov 5, 2026 |
| ETON | Eton Pharmaceuticals, Inc. | $62.62 | +34.20% | +285.12% | +262.38% | Nov 12, 2026 |
| FBRX | Forte Biosciences, Inc. | $76.99 | +0.44% | +226.09% | +589.87% | Nov 9, 2026 |
| OMER | Omeros Corporation | $18.22 | +61.52% | +11.23% | +328.71% | Nov 12, 2026 |
| AQST | Aquestive Therapeutics, Inc. | $5.39 | +43.35% | −16.43% | +40.00% | Nov 4, 2026 |
| 0KBU.L | Omeros Corporation | $18.44 | −4.75% | +11.14% | +332.86% | Nov 12, 2026 |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% | Sep 29, 2026 |
| CRDL | Cardiol Therapeutics Inc. | $2.14 | +78.33% | +115.29% | +91.07% | Nov 12, 2026 |
| CRDL.TO | Cardiol Therapeutics Inc. | 2.97 CAD | +74.71% | +118.38% | +90.38% | Nov 12, 2026 |
| CPIX | Cumberland Pharmaceuticals Inc. | $8.97 | +69.86% | +125.38% | +163.82% | Nov 3, 2026 |
| 0A8E.L | Xeris Biopharma Holdings, Inc. | $8.78 | +0.57% | +20.42% | +10.86% | Nov 5, 2026 |
| 0ABW.L | Egetis Therapeutics AB (publ) | 8.08 SEK | +8.09% | +63.15% | +58.43% | Nov 6, 2026 |
| 0K1R.L | Viridian Therapeutics, Inc. | $24.40 | +1.29% | −21.12% | +30.27% | Nov 5, 2026 |
| 0L49.L | SCYNEXIS, Inc. | $5.95 | +15.50% | +858.64% | +604.63% | Nov 4, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.